罗氏以17亿美元收购Ignyta

2018-01-02 MedSci MedSci原创

罗氏已经宣布计划以每股27美元的价格收购美国Ignyta集团，总价值约为17亿美元，确保获得后者的实验性癌症药物。位于加州圣地亚哥的Ignyta专注于肿瘤学的精准医学，旨在识别并治疗携带特定罕见突变的癌症患者。该公司的主要分子entrectinib，是一种口服生物可利用的CNS活性酪氨酸激酶抑制剂，用于治疗具有ROS1融合（非小细胞肺癌）或NTRK融合（跨越广泛的实体瘤）的肿瘤。该药目前正在进行关

罗氏已经宣布计划以每股27美元的价格收购美国Ignyta集团，总价值约为17亿美元，确保获得后者的实验性癌症药物。

位于加州圣地亚哥的Ignyta专注于肿瘤学的精准医学，旨在识别并治疗携带特定罕见突变的癌症患者。

该公司的主要分子entrectinib，是一种口服生物可利用的CNS活性酪氨酸激酶抑制剂，用于治疗具有ROS1融合（非小细胞肺癌）或NTRK融合（跨越广泛的实体瘤）的肿瘤。

该药目前正在进行关键的II期临床试验，如果成功，将支持NDA提交NTRK肿瘤和ROS1 NSCLC的申请。

来自STARTRK-2试验的ROSI融合阳性晚期非小细胞肺癌患者服用entrectinib的患者的数据显示，客观应答率为78％（25/32），中位应答持续时间为28.6个月，中位无进展生存期为29.6个月。

"癌症是一种非常复杂的疾病，许多患者都患有难以检测和治疗的突变。罗氏首席执行官丹尼尔o奥戴表示，公司与Ignyta达成的协议基于罗氏对患者的治疗策略，并将允许罗氏在全球范围内扩大和加强其肿瘤科业务。

交易预计将在2018年上半年完成。

原文出处：http：//www.pharmatimes.com/news/roche_to_buy_ignyta_for_$1.7_billion_1215007

此文系梅斯医学（MedSci)原创整理编译，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (4)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=275387, encodeId=5fa62e53870b, content=好好好祝贺祝贺, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Jan 04 13:31:05 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274977, encodeId=32f82e49778d, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 08:59:37 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274968, encodeId=74632e49685e, content=好有意见好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 03 08:28:30 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274841, encodeId=c4952e48415f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jan 02 22:22:41 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
2018-01-04 zwjnj2

好好好祝贺祝贺

73 0
[GetPortalCommentsPageByObjectIdResponse(id=275387, encodeId=5fa62e53870b, content=好好好祝贺祝贺, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Jan 04 13:31:05 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274977, encodeId=32f82e49778d, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 08:59:37 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274968, encodeId=74632e49685e, content=好有意见好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 03 08:28:30 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274841, encodeId=c4952e48415f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jan 02 22:22:41 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
2018-01-03 飛歌

厉害了我的哥

74 0
[GetPortalCommentsPageByObjectIdResponse(id=275387, encodeId=5fa62e53870b, content=好好好祝贺祝贺, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Jan 04 13:31:05 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274977, encodeId=32f82e49778d, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 08:59:37 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274968, encodeId=74632e49685e, content=好有意见好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 03 08:28:30 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274841, encodeId=c4952e48415f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jan 02 22:22:41 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
2018-01-03 thlabcde

好有意见好资料学习了!

65 0
[GetPortalCommentsPageByObjectIdResponse(id=275387, encodeId=5fa62e53870b, content=好好好祝贺祝贺, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Jan 04 13:31:05 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274977, encodeId=32f82e49778d, content=厉害了我的哥, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Jan 03 08:59:37 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274968, encodeId=74632e49685e, content=好有意见好资料学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92191944782, createdName=thlabcde, createdTime=Wed Jan 03 08:28:30 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274841, encodeId=c4952e48415f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Tue Jan 02 22:22:41 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
2018-01-02 天地飞扬

了解一下.谢谢分享!

74 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药品信息速递

罗氏以17亿美元收购Ignyta

相关资讯

科室

工具

服务